Alexandria maintains guidance while accelerating dispositions

Transcript intelligence

What changed

The company moved from a prior-quarter focus on reducing non-income-producing assets to a more defined 2026 plan: a $2.9 billion disposition program, lower capital expenditures, and continued megacampus and office-conversion work. Guidance was maintained, while the analysis newly highlights $1.45 billion of Q4 impairments and a Fenway conversion toward office use.

Guidance delta

Management maintained 2026 FFO, occupancy, and capex guidance while emphasizing lower capital expenditures and a $2.9 billion 2026 disposition program.

Key takeaways

• Management reported $1.5 billion of dispositions across 26 transactions and 1.2 million square feet of leasing, with occupancy at 90.9%.
• The current analysis describes maintained 2026 guidance, continued capex reduction, and a planned $2.9 billion disposition program focused on land and non-core assets.
• Demand remains uneven: private biotech funding was stable, while public biotech leasing was weak; quarterly rent headwinds from tenant wind-downs were identified.

Management priorities

• Execute the 2026 disposition program, emphasizing land and non-core assets.
• Reduce capital expenditures and progress megacampus expansion, including construction and entitlement work.
• Activate approximately 900,000 square feet of signed leases scheduled to start in Q3 2026 and pursue office-conversion opportunities.